287 related articles for article (PubMed ID: 25256166)
1. Mutational profiling of kinases in glioblastoma.
Bleeker FE; Lamba S; Zanon C; Molenaar RJ; Hulsebos TJ; Troost D; van Tilborg AA; Vandertop WP; Leenstra S; van Noorden CJ; Bardelli A
BMC Cancer; 2014 Sep; 14():718. PubMed ID: 25256166
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas.
Knobbe CB; Reifenberger G
Brain Pathol; 2003 Oct; 13(4):507-18. PubMed ID: 14655756
[TBL] [Abstract][Full Text] [Related]
3. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults.
Jha P; Suri V; Singh G; Jha P; Purkait S; Pathak P; Sharma V; Sharma MC; Suri A; Gupta D; Mahapatra AK; Sarkar C
Diagn Mol Pathol; 2011 Dec; 20(4):225-32. PubMed ID: 22089350
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
[TBL] [Abstract][Full Text] [Related]
6. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.
Ramkissoon SH; Bi WL; Schumacher SE; Ramkissoon LA; Haidar S; Knoff D; Dubuc A; Brown L; Burns M; Cryan JB; Abedalthagafi M; Kang YJ; Schultz N; Reardon DA; Lee EQ; Rinne ML; Norden AD; Nayak L; Ruland S; Doherty LM; LaFrankie DC; Horvath M; Aizer AA; Russo A; Arvold ND; Claus EB; Al-Mefty O; Johnson MD; Golby AJ; Dunn IF; Chiocca EA; Trippa L; Santagata S; Folkerth RD; Kantoff P; Rollins BJ; Lindeman NI; Wen PY; Ligon AH; Beroukhim R; Alexander BM; Ligon KL
Neuro Oncol; 2015 Oct; 17(10):1344-55. PubMed ID: 25754088
[TBL] [Abstract][Full Text] [Related]
7. IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients.
Stancheva G; Goranova T; Laleva M; Kamenova M; Mitkova A; Velinov N; Poptodorov G; Mitev V; Kaneva R; Gabrovsky N
Biomed Res Int; 2014; 2014():654727. PubMed ID: 24868540
[TBL] [Abstract][Full Text] [Related]
8. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q
Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605
[TBL] [Abstract][Full Text] [Related]
9. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
[TBL] [Abstract][Full Text] [Related]
11. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.
Mizoguchi M; Nutt CL; Mohapatra G; Louis DN
Brain Pathol; 2004 Oct; 14(4):372-7. PubMed ID: 15605984
[TBL] [Abstract][Full Text] [Related]
12. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
13. IDH1 and IDH2 mutations in gliomas.
Yan H; Parsons DW; Jin G; McLendon R; Rasheed BA; Yuan W; Kos I; Batinic-Haberle I; Jones S; Riggins GJ; Friedman H; Friedman A; Reardon D; Herndon J; Kinzler KW; Velculescu VE; Vogelstein B; Bigner DD
N Engl J Med; 2009 Feb; 360(8):765-73. PubMed ID: 19228619
[TBL] [Abstract][Full Text] [Related]
14. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
Song X; Andrew Allen R; Terence Dunn S; Fung KM; Farmer P; Gandhi S; Ranjan T; Demopoulos A; Symons M; Schulder M; Li JY
Int J Clin Exp Pathol; 2011; 4(7):651-60. PubMed ID: 22076165
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutations in glioblastoma multiforme.
Hartmann C; Bartels G; Gehlhaar C; Holtkamp N; von Deimling A
Acta Neuropathol; 2005 Jun; 109(6):639-42. PubMed ID: 15924253
[TBL] [Abstract][Full Text] [Related]
17. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
18. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA alterations in primary (de novo) and secondary glioblastomas.
Kita D; Yonekawa Y; Weller M; Ohgaki H
Acta Neuropathol; 2007 Mar; 113(3):295-302. PubMed ID: 17235514
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]